Literature DB >> 24237930

Anesthetic considerations for neonates undergoing modified Blalock-Taussig shunt and variations.

Helen M Holtby1.   

Abstract

The first Blalock-Taussig (BT) shunt was reported in 1944, and during the last 70 years, the procedure has evolved with the development of new materials and devices, and surgical approaches. It has, however, remained central to the palliation of neonates with complex congenital heart disease. The indications have expanded from the original aim of alleviating cyanosis and the pathophysiological results of chronic hypoxemia. They now include lesions with single ventricles, and rehabilitation of small pulmonary arteries. The physiology and hemodynamics of BT shunt circulations are very complex, and adverse hemodynamic events can be difficult to recognize. The consequences of shunt failure can be fatal, and the mortality (3-15%) and morbidity remain distressingly high even in the current era. Neonates undergoing BT shunt procedures or undergoing noncardiac surgery with this anatomy are challenging for the anesthesiologists to manage. There is a significant incidence of periprocedural cardiac arrest, often related to myocardial ischemia. A clear understanding of the anatomy and physiology is important. Any discussion of BT shunt in the current era has to include consideration of hypoplastic left heart syndrome and 'single ventricle' physiology.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Blalock-Taussig shunt; anesthesia; cardiac surgery; congenital heart disease; neonates

Mesh:

Year:  2013        PMID: 24237930     DOI: 10.1111/pan.12295

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  2 in total

Review 1.  The single ventricle pathway in paediatrics for anaesthetists.

Authors:  D Greaney; O Honjo; J D O'Leary
Journal:  BJA Educ       Date:  2019-03-06

Review 2.  New aspects of anesthetic management in congenital heart disease "common arterial trunk".

Authors:  Mohsen Ziyaeifard; Rasoul Azarfarin; Rasoul Ferasatkish
Journal:  J Res Med Sci       Date:  2014-04       Impact factor: 1.852

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.